Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

RCH-01's progress is uncertain, and there's skepticism about its effectiveness. Users are losing hope in this treatment.

A person shared their hair regrowth journey using HIMS topical treatments with finasteride, minoxidil, hormone replacement therapy (HRT), and microneedling. They also discussed their transition as a transgender woman and the positive impact of HRT on hair recovery.

The conversation discusses hair loss treatments, specifically RU58841, and inquiries about its availability and cost in India. Minoxidil and finasteride are also mentioned as treatments.

The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

The user experienced scalp irritation from a Finasteride and Minoxidil spray and serum. They are considering switching to foam, oral treatments, or another provider.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

Hair loss discussion mentions HMI-115 efficacy in 3 months after Phase II study. Users discuss treatment effectiveness and mention massive regrowth in previously bald areas.

HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Update on HMI-115 clinical trial expected in July or August.

A user who was part of an ongoing trial for a prolactin blocker and had regrowth, but the progress photos were not shared due to negative reactions from other users. Treatments mentioned include HMI-115, Minoxidil, Finasteride, and RU58841.

The conversation is about someone's hair regrowth progress using Hims serum from February 25th to April 6th. Users commented on the noticeable improvement and potential for full hair recovery.

The conversation discusses the HMI-115 trial for hair loss, which was expected to end around July 2023 due to a late participant. Participants also mention Minoxidil, finasteride, and RU58841 as treatments.

Hims reactivated a subscription without consent, leading to unauthorized charges for Finasteride and Minoxidil products, and refused to issue a refund until a bank dispute was filed. Users discussed alternative, cheaper sources for these treatments and shared similar negative experiences with Hims.

The conversation is about the delay in receiving updates on the HMI-115 phase 1 trial for hair loss. No specific treatments are mentioned in the conversation.

User reports 12-week progress with HIMS spray, Minoxidil, micro-needling, and biotin. Notable baby hairs on crown and temples, hoping for further improvement.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.

The post and conversation are about HMI-115, a potential treatment for hair loss. The conclusion is that HMI-115 is not a 5ar-inhibitor and is instead a prolactin receptor inhibitor. Some users are skeptical about its effectiveness and believe that baldness will still be a problem in the future.

The potential availability of a new hair loss treatment called HMI-115, which has shown promising results in experiments on monkeys but is not yet available to the public. Replies cautioned against using unproven substances from shady labs.

Cetirizine 10mg daily reduced hair shedding by 50% and lessened scalp itchiness. The user is considering long-term use for scalp inflammation and hair loss.

RU58841 helped reduce scalp itching for some users within a week, while others experienced immediate relief. Some users reported initial irritation from the solution, possibly due to the carrier used.

Dr. Tsuji and Riken announced a hair cloning cure with a 98.9% success rate, expected to be released in 10 years. Users expressed hope and skepticism about the affordability and timeline of the treatment.

Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. Users share experiences and support, mentioning that many people face hair thinning.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

HMI-115 shows promising hair growth and thickening in just 2 months. Results are positive but need more time for confirmation.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

A user found that taking Zyrtec (Cetirizine) and Advil helped reduce their scalp inflammation and pain, potentially creating a better environment for hair growth. They have not used any other medication for hair loss or scalp issues.

The user underwent a DHI hair transplant with 3,066 grafts at Hairtec in the Netherlands and is using finasteride and minoxidil to restore hair, particularly at the crown. They plan to adjust minoxidil dosage and consult with a dermatologist in September.